| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36310ab39fe797510fbf5c0408149b4f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5063
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5089
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4402 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4402
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate |
2021-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90d2364b07946ddfecb668cc42c5fb74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a15700efa1408ce4cfeceed254747539
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b34359309a9f124d8d09ffc89806a50b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_072f9a08d293b3d046e57c8760e6f346
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49173d503bce24980dd1a218b9a95f65 |
| publicationDate |
2022-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
PE-20221832-A1 |
| titleOfInvention |
AN ORAL DOSAGE FORM OF MULTIPLE MODIFIED-RELEASE UNITS OF DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE AND A PROCESS FOR THEIR PREPARATION |
| abstract |
The present invention relates to a modified release multiple unit oral dosage form comprising: a first plurality of doxylamine modified release microgranules comprising: a pharmaceutically acceptable inert core; an inner active coating layer comprising a doxylamine; optionally, an enteric release coating interlayer; and an outer layer of modified release coating; and a second plurality of modified release microgranules of pyridoxine or a pharmaceutically acceptable salt thereof comprising: an inert pharmaceutically acceptable core; an inner active coating layer comprising pyridoxine or a pharmaceutically acceptable salt thereof; and an outer layer of modified release coating; wherein the particle size of the pharmaceutically acceptable inert core of the first and second plurality of microgranules is such that at least 90% of the inert nuclei have a particle size of 300 micromol to 1,700 micromol and a particle size variability of not more than 200 µm measured by analytical sieving. It also refers to a process for its preparation and its use in therapy. |
| priorityDate |
2020-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |